



DALAL & BROACHA
STOCK BROKING PVT. LTD.

Analyst: Charulata Gaidhani (022) 67141446

Result update@ Dalal & Broacha

Neutral

Current Price	251
Target Price	273
Upside/Downside	9%
52 Week Range	212/320

Key Share Data

Market Cap (Rs.bn)	51.47
Market Cap (US\$ mn)	750.02
No of o/s shares (mn)	204.360s
Face Value	10
Monthly Avg. vol	
(BSE+NSE) Nos'000	386.99
BSE Code	539551
NSE Code	NH
Bloomberg	NARH:IN

Price performance



% Shareholding	June-18	Mar-18
Promoters	63.85	63.85
DII	23.33	21.21
FII	5.20	9.56
Others	7.62	7.38
Total	100	100

Narayana Hrudayalaya (NH) Q1FY19 results were below estimates. The lower occupancy at Whitefield, one of its top 3 hospitals and lower ARPOB at Cayman Islands are a concern to business. These along with higher overheads due to new hospitals at Mumbai and Delhi, and interest burden have resulted in a net loss of Rs 41 mn for the quarter. We reduce our rating to NEUTRAL in view of lack of visibility of earnings growth over the next few quarters.

Robust revenue growth, earnings hit due to lower occupancy and overheads

Revenues increased 25% yoy(1% qoq) to Rs 6523 mn. The NH India revenues increased 10% yoy with balance growth coming from Cayman Islands. EBITDA decreased 6% yoy (-10% qoq) to Rs 474 mn due to higher employee costs (+41% yoy, 6% qoq) and other expenses (+27% yoy, flat qoq). EBITDA margins were 240 bps lower yoy (-80 bps qoq) at 7.3%. PBT decreased 97% to Rs 6 mn. After taxes of Rs 30 mn and loss of associate of Rs 18 mn, NH incurred a net loss of Rs 41.4 mn. EPS was at Rs (-0.2).

Key takeaways from the concall

- Number of operating beds increased to 6143.
- NH India Occupancy was lower at 55% compared to 59% a year ago.
- During Q1FY19 Cayman ARPOB dropped from \$1.9 mn to \$1.5 mn yoy. Q1 is normally a weak quarter for Cayman.
- Overall ARPOB was 6% higher yoy (+4% qoq) at Rs 8.6 mn.
- During the quarter, NH has reduced 1 managed hospital representing 90 beds.
- NH plans to increase service offerings at SRCC Mumbai and Dharamshila New Delhi in order to improve ARPOBs and occupancy levels.

Revision of estimates

We have revised our estimates downwards for NH in view of the lower occupancy at Whitefield, Bengaluru which is expected to continue for the next 2 quarters and net loss in Q1FY19

Outlook & Valuation

The lower occupancy at Whitefield, Bengaluru, one of the top 3 hospitals of NH India and lower ARPOBs at Cayman Islands are a concern. Further, the increased overheads at its new hospitals namely SRCC (Mumbai), Dharamshila and Gurugram at Delhi and lower pace of growth in occupancy have reduced profitability. The loss in Q1FY19 and low visibility of improvement in earnings has come in as a major disappointment for NH. **We reduce our rating to NEUTRAL with a target price of Rs 273.**

Key Financials

Year	Net Sales	% Growth	EBIDTA	OPM (%)	PAT	% Growth	EPS	PE (x)	RoE (%)	RoCE (%)
FY16	16138.0	18%	1746.0	10.8%	213.0	-227%	1.04	251.3	2.4%	8.9%
FY17	18781.6	16%	2288.6	12.2%	830.5	290%	4.06	64.5	8.6%	11.8%
FY18	22809.1	21%	2122.7	9.3%	504.0	-39%	2.47	106.2	4.9%	6.4%
FY19E	26991.5	18%	2054.3	7.6%	318.1	-37%	1.56	168.3	3.1%	4.9%
FY20E	32459.8	20%	2759.5	8.5%	678.4	113%	3.32	78.9	6.4%	8.0%



DALAL & BROACHA
STOCK BROKING PVT. LTD.

Result update@ Dalal & Broacha

	Q1FY19	Q4FY18	Q1FY18	yoy	qoq	FY18	FY17	Var %
Income from operations	6523.4	6468.0	5211.1	25%	1%	22809.1	18781.6	21%
Other Income	30.0	42.5	52.3			189.0	174.8	
Total Income	6553.3	6510.5	5263.4	25%	1%	22998.1	18956.5	21%
Purchase of Medical Consumables & supplies	1612.7	1686.7	1537.4			5690.2	4388.8	
Inventory Change	-49.7	-74.8	-276.6			0.0	-29.8	
Employee Benefits	1508.9	1421.7	1072.5			4656.9	3752.1	
Professional Fees to Doctors	1369.1	1302.7	1104.9			4787.8	3855.7	
Other expenses	1608.2	1608.7	1268.9			5676.8	4526.3	
TOTAL EXPENSES	6049.3	5944.9	4707.1	29%	2%	20811.6	16493.1	26%
EBITDA (ex OI)	474.1	523.0	504.0	-6%	-9%	1997.4	2288.6	-13%
<i>EBITDA (ex-OI) margin</i>	<i>7.3%</i>	<i>8.1%</i>	<i>9.7%</i>			<i>8.8%</i>	<i>12.2%</i>	
EBIT	178.3	304.8	338.2	-47%	-42%	1312.1	1664.2	-21%
Interest	171.9	204.6	103.1			467.6	218.0	
Depreciation	325.8	260.8	218.2			999.5	799.2	
Profit Before Tax	6.4	100.2	235.1	-97%	-94%	844.6	1446.1	
Tax	30.0	-6.1	100.5			289.6	523.7	
Net Profit	-23.5	106.4	134.6	-117%	-122%	555.0	922.5	-40%
Minority Interest (after tax)	0.0	0.0	0.0			-10.0	0.8	
Profit/Loss of Associate Company	-17.9	-25.3	-25.4			-46.4	-79.3	
Net Profit after Minority Interest & P/L Asso.Co.	-41.4	81.1	109.2			498.6	843.9	-41%
Extraordinary items	0.0	17.0	0.0			5.4	-13.4	
Net Profit after extraordinary items	-41.4	98.1	109.2	-138%	-142%	504.0	830.5	-39%
NPM %	-0.6%	1.5%	2.1%			2.2%	4.4%	
Other comprehensive income	0.0	0.0	0.0			0.0	0.0	
Total comprehensive income	-41.4	98.1	109.2			504.0	830.5	
Equity	2043.6	2043.6	2043.6			2043.6	2043.6	
EPS after Minority Interest	-0.20	0.48	0.53			2.47	4.13	



DALAL & BROACHA
STOCK BROKING PVT. LTD.

Result update@ Dalal & Broacha

NARAYANA HRUDAYALAYA FINANCIALS											
	FY16	FY17	FY18	FY19E	FY20E		FY16	FY17	FY18	FY19E	FY20E
Profit & Loss (Rs mn)						Cash Flow St. (Rs. mn)					
Income from Operations	16,138	18,782	22,809	26,991	32,460	Net Profit	213	831	504	318	678
Purchase of medical consumables	3,871	4,359	5,565	6,478	7,790	Add: Dep. & Amort.	761	799	1,000	1,255	1,327
Employee costs	3,025	3,752	4,657	6,054	7,567	Cash profits	974	1,630	1,504	1,574	2,005
Professional fees to Doctors	3,522	3,856	4,788	5,668	6,654	(Inc)/Dec in					
Other expenses	3,974	4,526	5,677	6,737	7,688	-Sundry debtors	(89)	(51)	(1,221)	(538)	(674)
Cost of sales	14,392	16,493	20,686	24,937	29,700	-Inventories	15	(26)	(313)	(125)	(373)
Operating Profit	1,746	2,289	2,123	2,054	2,759	-Loans/advances	1,262	(161)	162	(11)	(12)
Depreciation	761	799	1,000	1,255	1,327	-Sundry creditors	209	(443)	2,339	327	974
PBIT	985	1,489	1,123	799	1,433	-Provisions	70	21	114	97	97
Other income	147	175	189	217	250	Change in working capital	1,467	(659)	1,082	(250)	12
Interest	294	218	468	587	624	CF from Oper. activities	2,441	970	2,585	1,324	2,017
Profit before tax	838	1,446	845	429	1,059	CF from Inv. activities	(3,625)	(1,405)	(8,030)	(635)	(2,398)
Provision for tax	301	524	290	103	365	CF from Fin. activities	1,373	492	5,850	(234)	(216)
PAT Bfr Excp Items	537	922	555	326	693	Cash generated/(utilised)	188	57	405	455	(596)
Minority Interest	4	1	(10)	(8)	(15)	Cash at start of the year	295	243	341	353	749
Share of Profit of Associate	(217)	(79)	(46)	-	-	Cash at end of the year	243	341	353	749	87
Extraordinary Items	(110)	(13)	5	-	-						
Net Profit	213	831	504	318	678						
Balance Sheet						Ratios					
Equity capital	2,044	2,044	2,044	2,044	2,044	OPM	10.8%	12.2%	9.3%	7.6%	8.5%
Reserves	6,716	7,587	8,314	8,223	8,493	NPM	1.3%	4.4%	2.2%	1.2%	2.1%
Net worth	8,760	9,631	10,357	10,267	10,537	Tax rate	36%	36%	34%	24%	35%
Def. Tax Liab.+Minority Int.	234	250	399	439	483	Growth Ratios (%)					
Secured loans	1,876	1,798	6,963	6,963	6,963	Net Sales	18%	16%	21%	18%	20%
Unsecured loans	478	1,023	1,421	1,421	1,421	Operating Profit	43%	31%	-7%	-3%	34%
Total debt	2,353	2,821	8,384	8,384	8,384	PAT	-227%	290%	-39%	-37%	113%
Other Liab	1,385	1,353	1,350	1,485	1,633						
CAPITAL EMPLOYED	12,732	14,055	20,490	20,574	21,036	Per Share (Rs.)					
Gross block	13,537	14,619	22,526	23,126	25,126	Net Earnings (EPS)	1.04	4.06	2.47	1.56	3.32
Accumulated depreciation	3,611	4,410	5,409	6,665	7,992	Cash Earnings (CPS)	4.77	7.97	7.36	7.70	9.81
Net block	9,927	10,209	17,117	16,461	17,134	Dividend	0.00	1.00	2.00	2.00	2.00
Capital WIP	138	530	350	250	500	Book Value	42.86	47.13	50.68	50.24	51.56
Total fixed assets	10,065	10,740	17,467	16,711	17,634	Free Cash Flow	-0.2	-2.3	-26.2	3.8	-1.4
Other Intangible assets	28	27	703	703	703	Valuation Ratios					
Goodwill	590	581	660	660	660	P/E(x)	251.3	64.5	106.2	168.3	78.9
Equity accounted Investees	869	928	37	37	37	P/B(x)	6.1	5.6	5.2	5.2	5.1
Investments	3	33	50	50	50	EV/EBIDTA(x)	30.6	23.3	25.1	26.0	19.3
Other non current assets	1,291	1,143	1,564	1,700	1,847	EV/SALES(x)	3.3	2.8	2.3	2.0	1.6
Inventories	497	524	836	961	1,334	Div. Yield(%)	0.0%	0.4%	0.8%	0.8%	0.8%
Sundry debtors	1,518	1,569	2,790	3,328	4,002	FCF Yield(%)	-0.1%	-0.9%	-10.0%	1.4%	-0.5%
Cash & bank	243	341	353	749	87						
Loans & advances	221	383	221	232	244	Return Ratios (%)					
Other current assets	240	199	593	653	718	ROE	2.4%	8.6%	4.9%	3.1%	6.4%
Sundry creditors	2,583	2,140	4,479	4,807	5,781	ROCE	8.9%	11.8%	6.4%	4.9%	8.0%
Provisions	252	273	387	484	580						
Working capital	(114)	603	(73)	632	23						
CAPITAL DEPLOYED	12,732	14,055	20,409	20,494	20,956						



DALAL & BROACHA
STOCK BROKING PVT. LTD.

Result update@ Dalal & Broacha

Disclaimer

Dalal & Broacha Stock Broking Pvt. Ltd, hereinafter referred to as D& B (CIN_U67120MH1997PTC111186) was established in 1997 and is an integrated financial services player offering an extensive range of financial solutions and services to a wide spectrum of customers with varied needs ranging from equities to mutual funds to depository services.

D&B is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). D&B along with its affiliates offers the most comprehensive avenues for investments and is engaged in the securities businesses including stock broking (Institutional and retail), depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.dalal-broacha.com

D&B is registered as Research Analyst with SEBI bearing registration Number INH000001246 as per SEBI (Research Analysts) Regulations, 2014.

D&B hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in any time in the past. It has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on D&B for certain operational deviations in routine course of business.

D&B offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by D&B (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

D&B or its associates may have financial interest in the subject company.

D&B or its associates do not have any material conflict of interest in the subject company.

The Research Analyst or Research Entity (D&B) has not been engaged in market making activity for the subject company.

D&B or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Disclosures in respect of Research Analyst:

Whether Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report:	No
Whether the Research Analyst or his/her relative's financial interest in the subject company.	No
Whether the research Analyst has served as officer, director or employee of the subject company	No
Whether the Research Analyst has received any compensation from the subject company in the past twelve months	No
Whether the Research Analyst has managed or co-managed public offering of securities for the	No



DALAL & BROACHA
STOCK BROKING PVT. LTD.

Result update@ Dalal & Broacha

subject company in the past twelve months	
Whether the Research Analyst has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report	No

D&B and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject D&B or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to D&B. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of D&B. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of D&B or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Contact	Email ID	Contact No.	Sector
Mr. Kunal Bhatia	kunal.bhatia@dalal-broacha.com	022 67141442	Auto, Auto Ancillary, FMCG
Ms.Charulata Gaidhani	charulata.gaidhani@dalal-broacha.com	022 67141446	Pharma /Chemicals
Mr. Mayank Babla	mayank.babla@dalal-broacha.com	022 67141412	IT, Media, Telecom
Mr. Avinash Kumar	avinash.kumar@dalal-broacha.com	022 67141441	Capital Goods
Ms Richa.Singh	richa.singh@dalal-broacha.com	022 67141444	Analyst

Address: - 508, Maker Chambers V, 221 Nariman Point, Mumbai 400 021

Tel: 91-22- 2282 2992, 2287 6173, (D) 6630 8667 Fax: 91-22-2287 0092

E-mail: research@dalalbroachaindia.com,
equity.research@dalal-broacha.com